Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

South Korea To Join U.S., U.K., Japan With New Bird Flu Vaccine

This article was originally published in PharmAsia News

Executive Summary

A South Korean veterinary professor says he has developed a vaccine for humans to guard against avian influenza to add to those developed in three other countries. The Chungnam National University professor said he developed the CNUK-H5N1-08-01 vaccine with a gene recombination technique to reduce the H5N1 toxicity. Along with the United States, the United Kingdom and Japan, South Korea now can produce a vaccine for people immune to existing vaccines. (Click here for more

You may also be interested in...



Sandoz Hits Back At Biosimilar Misinformation

Pierre Bourdage, global head of biopharmaceuticals at Sandoz, has hit back at false statements and misleading claims around biosimilars that persist despite mounting evidence to the contrary.

Spanish Consumer Health And Cosmetics Firms Eying Up China’s Online Self-Care Market

A recent Spanish self-care and cosmetics industry conference organized by ANEFP and Beauty Cluster explores the commercial opportunity in China via online marketplace Tmall. 

NeuClone Makes Progress On Ustekinumab

Australia’s NeuClone expects to be among the first biosimilar market entrants to challenge Stelara, with the firm’s NeuLara ustekinumab rival reporting positive Phase I data as the company prepares to move ahead with Phase III trials next year.

UsernamePublicRestriction

Register

OM013057

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel